Skip to content
lifestyle.cfxmagazine.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Halia Therapeutics
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
May 21, 2026
Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
March 2, 2026
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
December 8, 2025